Amplia Therapeutics Limited (ASX:ATX)
Australia
· Delayed Price · Currency is AUD 0.0540
+0.0030 (5.88%)
Apr 28, 2025, 4:10 PM AEST
Amplia Therapeutics Income Statement
Financials in millions AUD. Fiscal year is April - March.
Millions AUD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Other Revenue | 3.41 | 4.45 | 1.19 | 1.98 | 1.53 | 0.03 | Upgrade
|
| Revenue | 3.41 | 4.45 | 1.19 | 1.98 | 1.53 | 0.03 | Upgrade
|
| Revenue Growth (YoY) | 82.57% | 274.34% | -40.02% | 29.33% | 4380.44% | -32.19% | Upgrade
|
| Cost of Revenue | 0.4 | 0.44 | 0.31 | 0.15 | 0.31 | 0.12 | Upgrade
|
| Gross Profit | 3.01 | 4.01 | 0.88 | 1.83 | 1.22 | -0.09 | Upgrade
|
| Selling, General & Admin | 2.66 | 2.6 | 2.2 | 1.64 | 1.13 | 0.86 | Upgrade
|
| Research & Development | 6.41 | 5.8 | 4.69 | 3.77 | 2.21 | 1.07 | Upgrade
|
| Operating Expenses | 9.26 | 8.58 | 7.17 | 5.47 | 3.56 | 2.13 | Upgrade
|
| Operating Income | -6.25 | -4.57 | -6.29 | -3.64 | -2.34 | -2.22 | Upgrade
|
| Interest Expense | -0.09 | -0.08 | -0.05 | -0 | - | - | Upgrade
|
| Interest & Investment Income | 0.15 | 0.15 | 0.1 | 0 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -6.19 | -4.5 | -6.24 | -3.64 | -2.34 | -2.22 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.06 | - | Upgrade
|
| Pretax Income | -6.19 | -4.5 | -6.24 | -3.64 | -2.28 | -2.22 | Upgrade
|
| Net Income | -6.19 | -4.5 | -6.24 | -3.64 | -2.28 | -2.22 | Upgrade
|
| Net Income to Common | -6.19 | -4.5 | -6.24 | -3.64 | -2.28 | -2.22 | Upgrade
|
| Shares Outstanding (Basic) | 224 | 194 | 194 | 146 | 95 | 48 | Upgrade
|
| Shares Outstanding (Diluted) | 224 | 194 | 194 | 146 | 95 | 48 | Upgrade
|
| Shares Change (YoY) | 15.38% | 0.02% | 33.27% | 53.71% | 95.36% | 21.92% | Upgrade
|
| EPS (Basic) | -0.03 | -0.02 | -0.03 | -0.03 | -0.02 | -0.05 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.02 | -0.03 | -0.03 | -0.02 | -0.05 | Upgrade
|
| Free Cash Flow | -2.76 | -5.13 | -5.31 | -4.42 | -2.92 | -2.09 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.03 | -0.03 | -0.03 | -0.03 | -0.04 | Upgrade
|
| Gross Margin | 88.23% | 90.07% | 74.14% | 92.20% | 79.65% | -260.00% | Upgrade
|
| Operating Margin | -183.29% | -102.64% | -528.45% | -183.72% | -152.60% | -6495.43% | Upgrade
|
| Profit Margin | -181.41% | -101.14% | -524.80% | -183.74% | -148.75% | -6484.57% | Upgrade
|
| Free Cash Flow Margin | -80.89% | -115.20% | -446.19% | -222.68% | -190.52% | -6100.38% | Upgrade
|
| EBITDA | -6.24 | -4.56 | -6.28 | -3.64 | -2.34 | -2.22 | Upgrade
|
| EBITDA Margin | -182.97% | -102.40% | - | -183.56% | -152.56% | - | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | Upgrade
|
| EBIT | -6.25 | -4.57 | -6.29 | -3.64 | -2.34 | -2.22 | Upgrade
|
| EBIT Margin | -183.29% | -102.64% | - | -183.72% | -152.60% | - | Upgrade
|
| Revenue as Reported | 3.56 | 4.6 | 1.29 | 1.98 | 1.59 | 0.03 | Upgrade
|
Updated Nov 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.